Dr Boreham's Crucible: Regeneus
Biotech Daily: Dr Boreham’s Crucible: Regeneus
By TIM BOREHAM
Flush with fresh funding, the stem cell play’s overhauled management is supremely confident of striking a partnering deal in Japan pertaining to its lead osteoarthritis treatment Progenza.
90 Seconds With...Dr Alan Dunton
Interview with STOCKHEAD
Got 90 seconds? Then listen to Regeneus’ new board appointment Dr. Alan Dunton explain the opportunity presented by the global neuropathic pain market and Regeneus’ unique cell therapy offering.
Positive promise of stem cell therapy
Article from The Australian Financial Review
Taking on disease through regenerative medicine
Regenerating every cell, tissue or organ in the body, curing genetic disorders and chronic diseases, alleviating pain and delaying the onset of ageing, these are the altruistic promises of stem cell therapy.
Regeneus Presentation - FNN Investor Event
Regeneus CEO Leo Lee presents on the company's 1H19 results, its portfolio of novel cell-based therapies, progress with its Phase 2 trial of Progenza and strategy at FNN's Investor Event.
Regeneus prepares for global growth with appointment of life sciences industry leaders
Article from STAR INVESTING
Regeneus (ASX: RGS) has announced the appointments of John Chiplin, PhD and Alan W. Dunton, M.D. to its board of directors.
Interview with STOCKHEAD
Got 90 seconds? Then listen to Leo Lee, the CEO of regenerative medicine company Regeneus, following the appointment of two new board members.